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Background and aims: Postoperative pain after cesarean section is one of the import-
ant issues in gynecology. Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) 
are two of the drugs that are used for cesarean pain management. Considering the 
adverse effects of opioids in the mother and the baby, NSAIDs are preferred in the 
post-cesarean pain management. This study was designed to compare the effect of 
oral diclofenac potassium (Cataflam) with diclofenac sodium suppository on postoper-
ative cesarean pain.
Materials and methods: This randomized clinical trial was conducted on patients who 
underwent cesarean section in Taleghani Hospital during 2019. Patients were random-
ly divided into two groups based on flipping coin. The first group received 100 mg of 
oral diclofenac potassium every 6 hours and the second group received 100 mg of 
diclofenac sodium suppository every 6 hours. The pain was assessed 30 minutes, 2 
hours, 6 hours, 12 hours, 18 hours and 24 hours after the intervention using visual an-
alogue scale (VAS) before and after analgesics.
Results: Eighty-four patients were included in the final analysis. The mean of VAS 
during the intervention in the diclofenac sodium suppository group and in the Cata-
flam group was 3.42 ± 2.1 and 1.93 ± 2.4 respectively (P value = 0.011). Twenty-eight 
among 46 patients who received opioids due to severe pain (66.7%) were in the di-
clofenac suppository group and 18 of them (42.9%) were in the Cataflam group (P 
value = 0.021).
Conclusion: Diclofenac potassium tablets and diclofenac sodium suppository can re-
duce the post cesarean pain. The efficacy of diclofenac potassium tablets (Cataflam) is 
significantly higher than the diclofenac suppository; however, the complication rate was 
not significantly different.
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INTRODUCTION
Acute postoperative pain is one of the common complica-
tions after surgical operations which can cause different 
morbidities for patients [1]. Postoperative pain has a noci-
ceptive character and results from tissue and organ lesions 
in the acute phase and results from neuropathy and inflam-
mation in the chronic phase [2]. Inappropriate management 
of postoperative pain is associated with high rate of mor-
bidity, impaired quality of life; prolong hospital stay, slow 
recovery and increasing the costs of care [3]. 
Cesarean section is the most common inpatient surgical op-
eration in the world [4]. Acute postoperative pain is com-
mon after caesarian section [5]. Post cesarean section pain 
management is necessary for the efficient activity of moth-
er and the best care of the newborn [6]. Thus, uncontrolled 
pain may be associated with the delay in the bonding with 
the infant and increase the risk for thromboembolism due to 
limited mobilization [7]. 
Opioids were usually used for the management of postop-
erative caesarian pain; although, the rate of complications 
is high in the context of opioids consumption [8]. Recently, 
new analgesics and new techniques are used for the pain 
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received 100 milligrams of diclofenac suppository every 
six hours and another group was received 100 milligrams 
of diclofenac pill with the same dosage. The intervention 
was done by nurses who were blind from the study process. 
In addition, patients who had drug complications such as 
hypertension, dermatological complications, nausea and 
vomiting, were excluded from the study. Furthermore, in 
the study timelines (6th, 12th, 18th and 24th hours after the 
intervention), if the patients had VAS more than 3 in the 
concept of Cataflam or diclofenac suppository consump-
tion, 5 milligrams of morphine sulfate was used for the se-
dation of patients. 
Patients Assessment 
Mean arterial pressure (MAP) in addition to the pulse rate, 
the severity of pain related to visual analogue score (VAS) 
and the need for opioids were evaluated before the inter-
vention, 30 minutes after the intervention and at the sec-
ond, 6th, 12th, 18th and 24th hours after the intervention. 
In addition, the need for morphine sulfate in the PO time for 
each group of the intervention were evaluated at the end of 
the intervention.
Statistical Analysis 
All of the information was entered into the SPSS software 
version 15. Student t-test was used for comparing the se-
verity of pain between the two groups. Furthermore, Chi-
Square test was used for analyzing other variables in this 
study. 
Ethical Consideration 
This study was conducted after getting permission from the 
ethical committee of Shahid Beheshti University of Med-
ical Sciences with the registration number of: IR.SBMU.
MSP.REC.1395.405
RESULTS
One-hundred patients had the inclusion criteria and entered 
in the study at the baseline. Sixteen patients were excluded 
from the study due to personal reason. Eighty-four patients 
included in the final analysis. 
The mean age of patients was 32 ± 4.23. In addition, 40.4% 
reduction after caesarian section surgery instead of opioids 
usage [9]. Non-steroidal anti-inflammatory drugs (NSAIDs) 
are a common group of nonopioids analgesics that are used 
for pain management after obstetric surgeries [10]. 
Diclofenac is one of the NSAIDs that is used for post cae-
sarian pain control in recent studies [11]. However, the ef-
ficacy of different forms of diclofenac is still controversial. 
The aim of this study was to determine the effects of oral 
diclofenac potassium (Cataflam) and diclofenac sodium 
suppository on postoperative caesarian pain control
MATERIALS and METHODS
Study Design 
This study was a randomized double-blind clinical trial that 
was conducted on patients who underwent elective caesari-
an section in Taleghani Hospital during 2019. The inclusion 
criteria were age between 18 to 45 years. Patients who had 
the history of liver, kidney, cardiovascular and cerebrovas-
cular diseases in addition to hypertension, gastrointestinal 
bleeding, coagulation disorders, eclampsia, asthma and 
sensitivity to NSAIDs in addition to post-operative bleed-
ing were excluded from the study. Convenience sampling 
was used for sample selection; furthermore, flipping coin 
was used for randomization of the patients. 
Surgical Technique 
All patients underwent caesarian section by through of 
spinal anesthesia. Bupivacaine 0.5% with the dose of 12.5 
milligrams was injected spinally for patients; moreover, 
caesarian section was done for patients through Pfannen-
stiel incision. After the surgery, 5 milligrams of morphine 
sulfate were infused intravenously for primary sedation; in 
addition, morphine infusion was repeated in the context of 
severe pain every two hours in the NPO time. Moreover, 
patients who had VAS score more than 3 in the context 3 
doses of morphine sulfate were excluded from the study. 
Intervention 
After the surgical operation and primary sedation in the 
NPO time, patients were classified randomly to two groups 
with the allocation of 1:1 in the PO time. One group was 
Diclofenac potassium versus Diclofenac sodium in pain relief after CS
variable Diclofenac Sodium group (n=42) Cataflam group (n=42)
Age
18-24 10 (23.8%) 9 (21.4%)
25-31 16 (38.1%) 16 (38.1%)
32-38 14 (33.3%) 16 (38.1%)
39-45 2 (4.8%) 1 (2.4%)
Number of Pregnancies
1 16 (38.1%) 18 (42.9%)
2 18 (42.9%) 14 (33.3%)
3 4 (9.5%) 5 (11.9%)
More than 3 4 (9.5%) 5 (11.9%)
Number of C/S
1 27 (64.3%) 25 (59.5%)
2 14 (33.3%) 16 (38.1%)
3 0 (0%) 1 (2.4%)
More than 3 1 (2.4%) 0 (0%)
TABLE 1. Demographic Factors of the patients
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of patients did not have the history of previous pregnancies. 
Moreover, 61.9% of samples did not have the history of 
caesarian sections. 
The results of other demographic factors are presented in 
Table 1. 
The mean MAPs, the mean of pulse rate per minute and 
the mean Visual Analogue Score (VAS) of the patients in 
the study intervals are presented in Table 2, 3 and 4 respec-
tively. 
Need for Opioids 
Forty-six patients (54.7%) were received opioids in addi-
tion to the interventions due to severe pain. Twenty-eight 
among 46 (66.7%) were in the diclofenac suppository 
group and 18 of them (42.9%) were in the Cataflam group 
(P value = 0.021). 
Drug Side Effects 
Sixteen patients (19.04%) had drug related side effects 
which seven of them were in the diclofenac suppository 
group (43.75%) and 9 of them were in the Cataflam group 
(56.25%). There are not any significant differences between 
the two groups in the drug side effects (P value = 0.235). 
DISCUSSION
In the current study, the amount of pain in the patients that 
measure with Visual Analogue Scale (VAS), decreased sig-
nificantly in both groups of intervention which can be re-
lated to the effect of analgesics, wound healing process and 
patients stress.  Moreover, the mean Visual Analogue Score 
(VAS) of the patients at the second, 6th, 12th, 18th and 24th 
hours after C/S in the Cataflam group is lower than the Di-
clofenac sodium group ((Table 4). It is concluded that Cata-
flam is more effective for the post caesarian pain in patients 
in compare to Diclofenac suppository. The analgesic effects 
of Cataflam tablets have been confirmed in other studies [12, 
13]. In addition, the high efficacy of Diclofenac sodium sup-
pository in reducing postoperative pain, especially perineal 
pain, has been demonstrated in other studies [14, 15]. Con-
suming NSAIDs after the caesarian section for pain relief 
can reduce the need for opioids [16]. In this study, the need 
for opioids in the Cataflam group was lower than Diclofenac 
suppository group. 
Considering the results of this study, the mean MAP was not 
significantly different between the two groups after the inter-
vention. This result was in line with the findings of Dilger et 
al. who stated that short-term use of diclofenac did not affect 
the blood pressure [17]. However, many studies have sug-
gested that Diclofenac inhibition effect on COX-2 increases 
Soodabeh Darvish et al.
 Variable  Diclofenac Suppository group  Cataflam group
MAP
 Before the intervention 98.2 ± 12.3 (95% CI 93.3-103) 97.4 ± 14.6(95% CI 91.6-103) 0.7
30 minutes after the intervention 97.5 ± 18.7 (95% CI 90-105) 98.6 ± 8.6 (95% CI 95.2-102)  0.8
2 hours after the intervention 93.9 ± 11.4 (95% CI 89.3-98.5) 97.1 ± 10.5 (95% CI 92.9-101)  0.4
6 hours after the intervention 95.7 ± 19.8 (95% CI 87.8-104) 97.8 ± 21.3 (95% CI 89.3-106)  0.5
12 hours after the intervention 94.3 ± 20.4 (95% CI 86.1-102) 95.2 ± 33.1 (95% CI 82-108)  0.4
24 hours after the intervention 94.1 ± 15.5 (95% CI 87.9-100) 96.5 ± 16.9 (95% CI 89.7-103)  0.5
TABLE 2. Mean arterial pressure in the patients 
 Variable  Diclofenac Suppository group  Cataflam group
Pulse 
Rate
 Before the intervention 95.1 ± 10.2(95% CI 91-99.2) 93.3 ± 11.3(95% CI 89.9-96.7) 0.6
30 minutes after the intervention 93 ± 12.1(95% CI 88.2-97.8) 92.4 ± 13.6(95% CI 88.3-96.5) 0.6
2 hours after the intervention 89.5 ± 16.3(95% CI 83-96) 89.1 ± 18.6(95% CI 83.5-94.7) 0.8
6 hours after the intervention 85.6 ± 9.8(95% CI 81.7-89.5) 84.2 ± 14.7(95% CI 79.8-88.7) 0.7
12 hours after the intervention 83.7 ± 8.4(95% CI 80.3-87.1) 83.4 ± 7.5(95% CI 81.1-85.7) 0.9
24 hours after the intervention 80.6 ± 5.4(95% CI 78.4-82.8) 78.2 ± 6.5(95% CI 76.2-80.2) 0.7
TABLE 3. Mean pulse rate per minute in the patients 
 Variable  Diclofenac Suppository group  Cataflam group
MAP
 Before the intervention 5.25 ± 2.3(95% CI 4.55-5.95) 5.43 ± 1.8(95% CI 4.89-5.97) 0.2
30 minutes after the intervention 4.99 ± 1.9(95% CI 4.42-5.57) 5.01 ± 2.2(95% CI 4.34-5.67) 0.15
2 hours after the intervention 3.85 ± 1.4(95% CI 3.43-4.27) 3.05 ± 0.9(95% CI 2.78-3.32) 0.02
6 hours after the intervention 2.98 ± 1.1(95% CI 2.65-3.31) 2.03 ± 1.4(95% CI 1.61-2.45) 0.018
12 hours after the intervention 2.09 ± 0.9(95% CI 1.82-2.36) 1.18 ± 0.8(95% CI 0.938-1.42) 0.012
24 hours after the intervention 1.25 ± 0.7(95% CI 1.04-1.46) 0.84 ± 0.5(95% CI 0.689-0.991) 0.01
TABLE 4. Mean VAS in the patients 
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blood pressure, which is not associated with our findings 
[18, 19]. It seems that the period of Diclofenac consuming 
is related to its effect on blood pressure; in the other hand, 
the negative effects of Diclofenac on blood pressure may 
be manifest in long term use of this drug instead of a 24 
hours period. 
In this study, the mean heart rate per minute before the in-
tervention was significantly higher in compare to the after 
the intervention. This finding is consistent with the results 
of the study of Hinz et al. and Ibrahim et al. [18, 20]. In fact, 
the study found that Cataflam and Diclofenac suppository 
both can significantly reduce the heart rate in patients; al-
though, there are not any differences between two of them.
CONCLUSION
Diclofenac potassium pill (Cataflam) is more efficient than 
Diclofenac sodium suppository in the pain reduction after 
caesarian section. Moreover, Cataflam consumption can be 
related to lower dose of opioid use after caesarian section,
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